Focused On-demand Library for Transcriptional enhancer factor TEF-4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q15562

UPID:

TEAD2_HUMAN

Alternative names:

TEA domain family member 2

Alternative UPACC:

Q15562; B4DTJ6; M0R1T9; Q8NA25; Q96IG3

Background:

Transcriptional enhancer factor TEF-4, also known as TEA domain family member 2, is a pivotal transcription factor in the Hippo signaling pathway. This pathway is crucial for organ size control and tumor suppression, functioning through the restriction of proliferation and promotion of apoptosis. TEF-4 facilitates the gene expression of YAP1 and WWTR1/TAZ, key oncoproteins, thereby influencing cell proliferation, migration, and the induction of epithelial mesenchymal transition (EMT). It specifically binds to the SPH and GT-IIC enhansons, playing a role in neural development and gene regulation via the M-CAT motif.

Therapeutic significance:

Understanding the role of Transcriptional enhancer factor TEF-4 could open doors to potential therapeutic strategies.